CEDAR KNOLLS, NJ--(Marketwired - Feb 11, 2015) - MYOS Corporation ("MYOS" or the "Company") (MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today that it has been selected to present research at the Keystone Symposia's Conference on the Human Proteome to be held April 24-29, 2015 in Stockholm, Sweden. Keystone Symposia on Molecular and Cellular Biology is a peer-reviewed conference that connects the scientific community and accelerates life science discovery.
MYOS has developed a novel bioanalytical methodology for proteome mapping using multi-dimensional separations and accurate mass, high resolution mass spectrometry. This methodology has been used to study the early changes that take place in hen egg yolk upon fertilization at the proteomic-level and may also be useful for human proteome studies as well. Fertilized chicken egg yolk is the source of active proteins in Fortetropin™, a unique orally administered dietary supplement clinically shown to reduce serum myostatin levels and increase lean body mass and muscle thickness. Recently, MYOS has also demonstrated in preclinical studies that Fortetropin upregulates the mTOR pathway, an important pathway for the synthesis of muscle proteins, and down-regulates the ubiquitin pathway, a pathway involved in muscle protein degradation. MYOS is working to further characterize beneficial proteins, lipids and other bioactive molecules found in Fortetropin.
Commenting on these research activities, Robert Ashton, M.D., Chief Medical Officer of MYOS said, "An important focus of our research and development strategy going forward is to capitalize on recent advances in proteomics, metabolomics and lipidomics to identify, characterize and isolate unique proteins, peptides, lipids and/or small molecules found in Fortetropin with therapeutic potential. We expect that recent technological advances in proteome mapping will help propel this effort forward."
Robert J. Hariri, M.D., Ph.D., Chairman of the Board of MYOS, added, "As an emerging biotherapeutics company focused on improving muscle health, the ability to comprehensively elucidate the changes that take place in the proteome of egg yolk upon fertilization is of great importance to us. Many of the exciting technological advances that have taken place in the last five years due to the challenges faced in completing the Human Proteome Project will be of great benefit to researchers who are working on mapping the proteome of other species."
About MYOS Corporation
MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin™, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com.
The Company's first commercial product containing Fortetropin (MYO-T12), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X® and is currently available on popular retailer websites including http://mhpstrong.com, www.bodybuilding.com, www.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin™ and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, customer demand for our products, market acceptance of our existing and future products, the ability to create new products through research and development including the research described herein, growth in our revenue, the successful entry into new markets including the age management market, the ability to successfully develop and launch our own core branded products, the ability to collect our accounts receivable from our distributors, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin and MYO-X®, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to enter into strategic relationships with new distributors, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.